We are live on
!
Find out more
VVM
Versant Venture Management Portfolio holdings
AUM
$163M
1-Year Est. Return
240.43%
This Fund
S&P 500
This Quarter
Est. Return
+51.11%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$98.7M
AUM Growth
-$39.8M
(-29%)
Cap. Flow
-$64.2M
Cap. Flow
% of AUM
-65.04%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$44.4M |
| 2 |
Glaukos
GKOS
|
+$12.7M |
| 3 |
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
|
+$7.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Glaukos
GKOS
$10.1B
| $75.4M | 76.45% |
2,586,985
-549,247
| -18% | -$12.7M |
|
2
Ocular Therapeutix
OCUL
$2.35B
| $11M | 11.11% |
2,215,384
| – | – |
|
|
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.59M | 5.66% |
407,416
| – | – |
|
|
AKAO
4
DELISTED
Achaogen Inc
AKAO
| $4.86M | 4.92% |
1,281,152
| – | – |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $1.82M | 1.85% |
1,048,601
| – | – |
|
|
FPRX
6
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-1,092,152
| Closed | -$44.4M |
|
|
BITI
7
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
| – | – |
-268,672
| Closed | -$7.09M |
|
Similar funds
TC
GF
ACM
KFS
VB
RWA
CCM
GCM
Versant Venture Management's Q2 2016 Portfolio in Review
As of Q2 2016, Versant Venture Management held 7 positions worth $98.7M, down 29% from $139M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Versant Venture Management withdrew a net $64.2M in Q2 2016, closing 2 positions and reducing 1 holding. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $44.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.
- Versant Venture Management's biggest Q2 2016 reduction was Glaukos, cutting an estimated $12.7M.
- Versant Venture Management fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $44.4M.
- Versant Venture Management's ten largest holdings make up 100% of its $98.7M portfolio in Q2 2016.
- Versant Venture Management opened 0 new positions and closed 2 in Q2 2016.
- Versant Venture Management's portfolio value fell 29% quarter-over-quarter to $98.7M.
Based on Versant Venture Management's 13F filing for Q2 2016, filed 28 Jul 2016.